Allergan And Medicis/Ipsen Battle Over Marketing Advantage Of REMS

FDA's decision to require a Risk Evaluation and Mitigation Strategy for botulinum toxin products has opened up a marketing battle between Allergan's long-standing Botox and Ipsen/Medicis' the new-to-the-block Dysport

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet